Pfizer ( PFE) shares gained on Tuesday after the New York-based pharma giant reported better-than-expected financials for Q2 2025 and increased its full-year earnings outlook, citing, among other ...

Here is why Pfizer's newfound momentum could set the stock up to soar in 2026. Pfizer's generous dividend has become a big ...

SERB Pharmaceuticals plans to buy Y-mAbs Pharmaceuticals in a $412 million all-cash deal. CorMedix bought Melinta ...

In early corporate news, GSK wins a payout after settlement is reached in the legal action between partner CureVac and BioNTech on Thursday, while Renewables Infrastructure posts a widened interim ...

Pfizer Inc. (NYSE: PFE) delivered a stronger-than-anticipated second-quarter performance, beating analyst estimates and ...

Drugmaker Viatris beat Wall Street estimates for second-quarter profit and revenue on Thursday, helped by demand for its products in China, sending its shares up nearly 5% in early trading.

The dividend yield investors could receive from Pfizer stock has risen from about 3% in early 2022 to 7% when the market ...

The tariff threat come just a few days after the White House sent letters to major drugmakers demanding slashed prices for US patients.

Key Points Non-GAAP EPS was ($0.13), missing the consensus estimate by $0.02 (non-GAAP), due to higher pre-commercialization spending. Research and development expenses fell 48.2% compared to Q2 2024, ...

Shares in the data-software company were up 7.8% Tuesday after it posted higher quarterly results and [boosted its annual ...

Chief Executive Albert Bourla says he is hopeful about finding a solution in response to Trump’s demand for price cuts.

The Santa Clara, Calif., chip maker logged an increase in profit and sales for its latest quarter on record server and personal computer processor sales. Fifteen of the biotechnology company's ...